Henlius Revenue and Competitors
Estimated Revenue & Valuation
- Henlius's estimated annual revenue is currently $79.4M per year.
- Henlius's estimated revenue per employee is $155,000
Employee Data
- Henlius has 512 Employees.
- Henlius grew their employee count by -2% last year.
Henlius's People
| Name | Title | Email/Phone |
|---|
Henlius Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Henlius?
Founded in 2009, Shanghai Henlius Biotech, Inc. (Henlius) is a global clinical-stage company focusing on the discovery, development, manufacturing and commercialization of high-quality and innovative biologics to treat a range of chronic and life-threatening diseases. With a team of over 600 employees in Shanghai, Beijing, Taipei and Bay Area, Henlius brings a combined leadership, global drug development and biologic manufacturing experience of 200+ years, and is determined to bring the meaningful therapeutic solutions for patients. For more information, please visit www.henlius.com Henlius pipeline includes 11 clinical-stage product candidates with 24 successful IND/CTA filings (14 approvals from China; 3 from the United States; 3 from Taiwan; 1 from the European Union; 1 from Ukraine; 1 from Philippines and 1 from Australia). In October 2017, Henlius submitted its first New Drug Application (NDA) of HLX01 (Rituximab Injection) to CFDA, which granted for priority review in early 2018, making HLX01 potentially the first approved biosimilar in China.
keywords:N/A
N/A
Total Funding
512
Number of Employees
$79.4M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Henlius News
Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for...
Henlius has carried out a comprehensive first-line immune-oncology treatment layout for LC in sqNSCLC, non-squamous non-small cell lung cancer (...
HANSIZHUANG (recombinant humanized anti-PD-1 monoclonal antibody injection, generic name: serplulimab injection) is the first innovative...
Other Companies in shanghai
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $131.5M | 513 | 1% | N/A |
#2 | $183.6M | 534 | 0% | N/A |
#3 | $9570M | 699 | 5% | N/A |
#4 | $126.9M | 700 | 1% | N/A |
#5 | $151.4M | 746 | -2% | N/A |